InnoCare Pharma Limited announced that on 30 June 2026 its Board granted 1.91 million restricted share units (RSUs) to eight employees under the 2023 Share Award Scheme, representing about 0.11% of the company’s issued share capital (excluding treasury shares).

Breakdown of the grant • Senior management: 450,000 RSUs were awarded to one senior executive. • Other employees: 1.46 million RSUs were allocated to seven staff members deemed critical to InnoCare’s development.

Key terms • Purchase price: US$0.178 (approximately HK$1.39) per share. • Market reference: The company’s shares closed at HK$11.86 on the 30 June 2026 grant date. • Vesting: 1.48 million RSUs vest in four equal tranches over one to four years. The remaining 430,000 RSUs are subject to performance-based vesting; the timetable depends on achieving pre-set corporate targets (operating revenue and clinical-trial milestones) and individual performance metrics. • Clawback: Vested or unvested RSUs can be forfeited if a recipient commits misconduct, breaches laws, violates company policies, or fails to meet non-compete obligations.

Scheme capacity Prior to the grant, the scheme’s trustee held 26.28 million shares. Following the issue, 24.37 million shares remain available for future awards, including 1.76 million reserved for service providers.

Governance and compliance None of the eight grantees is a director, chief executive, substantial shareholder, related-entity participant, or service provider of InnoCare, and no individual award exceeds the 1% cap stipulated under Hong Kong Listing Rule 17.03D. Consequently, shareholder approval was not required.

Strategic rationale The Board stated that the RSU allocation aims to recognise past contributions, align employee interests with shareholder value, incentivise performance tied to commercialisation and R&D milestones, and support talent retention for long-term growth.